Tellus Therapeutics was founded in 2018 as a neonatal care company whose mission is to develop safe and effective treatments for newborns in the neonatal intensive care unit (NICU). One in ten babies is born premature and at significant risk for white matter (myelin) injury and subsequent lifelong cognitive and neurological impairments, such as cerebral palsy. Tellus' novel small molecules have demonstrated ability to induce regeneration of myelin-producing oligodendrocytes and reverse white matter injury in animal models of perinatal brain injury. Tellus' TT-20 has been granted Rare Pediatric Disease and Orphan Drug Designations and is completing IND-enabling studies to support a Phase 1b trial in premature infants at risk for brain injury. The potential of the Tellus platform extends beyond treatment of neonatal brain injury into neonatal respiratory and gastrointestinal disorders, including bronchopulmonary dysplasia and necrotizing enterocolitis.

**Therapeutic Focus:** CNS/Neurological, Orphan/Rare Disease, Regenerative Medicine

**Development Program:** TT-20 is in late preclinical development having initiated drug product formulation, IND-enabling work and preparation for a pre-IND meeting in the next year.

**Regulatory Pathway:** Tellus is pursuing a strategy for market authorization utilizing available FDA regulatory mechanisms, E.g., Orphan Drug Designation, Breakthrough Therapy, FastTrack and Accelerated Approval, to safely and efficiently bring TT20 to newborns with brain injury.

**Current Investors:** Xontogeny

**Unmet Need:** Tellus is developing the first treatment to prevent white matter brain injury in babies born premature and to improve neurodevelopment outcomes, including incidence and severity of cerebral palsy.

**Competitive Advantage:** Tellus is developing the only small molecule therapeutic targeting the repair of white matter brain injury in premature infants.

**Funding Raised to Date:** $3.6 million in Seed and non-dilutive funding

**Go-to-Market Strategy:** Tellus is pursuing a strategy for market authorization utilizing available regulatory mechanisms and incentives and will serve the hospital neonatal intensive care units who provide care for neonatal patients.